U.S. markets closed

Aerpio Pharmaceuticals Inc (ARPO) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Aerpio Pharmaceuticals Inc (ARPO) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Aerpio Pharmaceuticals Inc is a biopharmaceutical company. It focuses on advancing first-in-class treatments for ocular diseases. Aerpio Pharmaceuticals Inc has a market cap of $120.952 million; its shares were traded at around $2.98 with and P/S ratio of 5.87.

For the last quarter Aerpio Pharmaceuticals Inc reported a revenue of $0.00 million, compared with the revenue of $0.00 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $20.2 million,

The reported loss per diluted share was 31 cents for the year. The Aerpio Pharmaceuticals Inc had an operating margin of -55.47%, compared with the operating margin of 0% a year before. The profitability rank of the company is 5 (out of 10).

At the end of the fiscal year, Aerpio Pharmaceuticals Inc has the cash and cash equivalents of $62.6 million, compared with $20.3 million in the previous year. The company had no long term debt. The interest coverage to the debt is 3.2. Aerpio Pharmaceuticals Inc has a financial strength rank of 10 (out of 10).

At the current stock price of $2.98, Aerpio Pharmaceuticals Inc is traded at close to its historical median P/S valuation band of $3.30. The P/S ratio of the stock is 5.87, while the historical median P/S ratio is 6.50. The stock lost 31.49% during the past 12 months.

For the complete 20-year historical financial data of ARPO, click here.

This article first appeared on GuruFocus.